11月3日，建发致新涨3.98%，成交额4.76亿元。两融数据显示，当日建发致新获融资买入额3103.98万 元，融资偿还2824.12万元，融资净买入279.86万元。截至11月3日，建发致新融资融券余额合计9757.93 万元。 融资方面，建发致新当日融资买入3103.98万元。当前融资余额9757.93万元，占流通市值的5.75%。 融券方面，建发致新11月3日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 资料显示，上海建发致新医疗科技集团股份有限公司位于上海市杨浦区杨树浦路288号9层，成立日期 2010年8月30日，上市日期2025年9月25日，公司主营业务涉及从事医疗器械直销及分销业务,并为终端 医院提供医用耗材集约化运营(SPD)服务。主营业务收入构成为：血管介入55.61%，外科器械21.46%， 检验试剂(IVD)13.05%，医疗设备6.24%，其他医疗器械2.79%，SPD及其他服务0.63%，其他(补 充)0.23%。 截至9月30日，建发致新股东户数3.80万，较上期增加151.60%；人均流通股1327股， ...

Core Viewpoint - Jianfa Zhixin, a subsidiary of Xiamen Jianfa Group, is set to be listed on the Shenzhen Stock Exchange on September 25, 2025, focusing on high-value medical device distribution and supply chain services in China [1] Group 1: Company Overview - Jianfa Zhixin was established on August 30, 2010, and is headquartered in Shanghai [1] - The company operates in the medical device direct sales and distribution sector, providing centralized operation services for medical consumables to hospitals [1] Group 2: Financial Performance - For Q3 2025, Jianfa Zhixin reported revenue of 14.861 billion yuan, ranking 12th in the industry, while the industry leader, Shanghai Pharmaceuticals, reported revenue of 215.072 billion yuan [2] - The net profit for the same period was 284 million yuan, placing the company 11th in the industry, with the top performer, Shanghai Pharmaceuticals, achieving a net profit of 5.986 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Jianfa Zhixin's debt-to-asset ratio was 83.52%, exceeding the industry average of 59.74% [3] - The company's gross profit margin was 7.98%, which is below the industry average of 13.11% [3] Group 4: Management and Shareholder Information - The chairman, Yu Feng, has a salary of 1.8949 million yuan for 2024, while the general manager, Wu Shengyong, has a salary of 2.7466 million yuan [4] - The controlling shareholder is Xiamen Jianfa Medical Health Investment Co., Ltd., with actual control by the Xiamen Municipal Government's State-owned Assets Supervision and Administration Commission [4] Group 5: Shareholder Dynamics - As of September 30, 2025, the number of A-share shareholders increased by 151.60% to 38,000, while the average number of circulating A-shares held per shareholder decreased by 60.25% to 1,327.4 [5] - The company is recognized for its strong backing from the Xiamen State-owned Assets Supervision and Administration Commission and its integration of information management with traditional medical device distribution [5]

Group 1 - Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. successfully held its IPO ceremony on September 25 [2] - The company, founded in 2010 and headquartered in Shanghai, is a national medical device distributor and part of the C&D Group [3] - The company engages in direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals, maintaining long-term partnerships with over 100 well-known domestic and international high-value medical device manufacturers [3] Group 2 - Chairman Yu Feng emphasized that the company will leverage its listing as an opportunity to utilize capital market resources, focusing on industry pain points and enhancing hospital scenarios [9] - The company aims to embrace the intelligent era and actively serve the public and society, with a commitment to delivering better operational performance to shareholders and contributing to society [9]

Core Viewpoint - C Jianfa Zhi (301584) experienced a significant increase of 418.58% on its first trading day, with a turnover rate of 83.19% and a transaction volume of 1.477 billion yuan [2][3]. Group 1: Stock Performance - On its debut, C Jianfa Zhi's stock price surged by 418.58% [2]. - The stock achieved a turnover rate of 83.19% on the first day of trading [2]. - The total transaction amount for the stock on its first day reached 1.477 billion yuan [2]. Group 2: Financing and Trading Data - The financing buy-in amount for C Jianfa Zhi on its first trading day was 53.5614 million yuan, accounting for 3.63% of the total trading volume [2]. - The latest financing balance for the stock stood at 47.1425 million yuan, representing 2.56% of its circulating market value [2]. - The stock saw a net inflow of 450 million yuan from major funds on its first day, with large orders contributing 217 million yuan and 233 million yuan respectively [3]. Group 3: Market Activity - The top five trading departments on the stock's first day had a combined transaction volume of 140 million yuan, with a net buying amount of 68.3308 million yuan [3]. - Among the top trading departments, two institutional special seats were involved, with a total net selling of 10.2238 million yuan [3].

Group 1 - N Jianfa Zhi (301584) was listed today, opening with a surge of 410.64%, and closing with an increase of 418.58%, with a total trading volume of 41.9468 million shares and a turnover of 1.477 billion yuan, resulting in a turnover rate of 83.19% [2] - The company primarily engages in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to terminal hospitals [3] - The total issuance volume for this IPO was 63.1933 million shares, with an online issuance volume of 20.8535 million shares, priced at 7.05 yuan per share, and an issuance P/E ratio of 13.29, compared to the industry average P/E ratio of 25.73 [3] Group 2 - The final online subscription rate for the IPO was 0.0198472227%, and the total fundraising amount was 446 million yuan, primarily allocated for working capital, information system upgrades, and centralized operation service projects for medical consumables [3] - Other newly listed stocks today included N Lianhe Dong (301656), which rose by 147.60% with a turnover rate of 74.57%, and N Jinhua (920015), which increased by 133.00% with a turnover rate of 91.23% [2][3]

统计显示，公司本次发行总量为6319.33万股，其中，网上发行量为2085.35万股，发行价格为7.05元/ 股，发行市盈率13.29倍，行业平均市盈率25.73倍，网上发行最终中签率为0.0198472227%。公司首发 募资金额为4.46亿元，募资主要投向补充流动资金、信息化系统升级建设项目、医用耗材集约化运营服 务项目等。（数据宝） 今日上市新股表现 N建发致(301584)今日上市，开盘上涨410.64%，截至上午收盘涨幅扩大至514.18%，半日成交量3496.43 万股，成交额12.15亿元，换手率69.34%。 证券时报·数据宝统计显示，今日共有3只新股上市，截至上午收盘，N建发致涨514.18%，换手率 69.34%；N联合动涨168.67%，换手率56.45%；N锦华涨147.99%，换手率77.64%。 公司主要从事医疗器械直销及分销业务，并为终端医院提供医用耗材集约化运营(SPD)服务。 | 代码 | 简称 | 最新价（元） | 上午收盘涨跌幅（%） | 半日换手率（%） | | --- | --- | --- | --- | --- | | 301584 | N建发致 | 43.30 ...

公司主要从事医疗器械直销及分销业务，并为终端医院提供医用耗材集约化运营(SPD)服务。 证券时报·数据宝统计显示，公司本次发行总量为6319.33万股，其中，网上发行量为2085.35万股，发行 价格为7.05元/股，发行市盈率13.29倍，行业平均市盈率25.73倍，网上发行有效申购户数为1347.22万 户，网上发行最终中签率为0.0198472227%。公司首发募集资金4.46亿元，募集资金主要投向补充流动 资金、信息化系统升级建设项目、医用耗材集约化运营服务项目等。（数据宝） 近期上市新股首日表现 N建发致今日上市，开盘价36.00元，上涨410.64%。 | 代码 | 简称 | 上市日期 | 发行价（元） | 发行市盈率（倍） | 首日开盘涨跌幅（%） | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | 301584 | N建发致 | 2025.09.25 | 7.05 | 13.29 | 410.64 | 医药生物 | | 301656 | N联合动 | 2025.09.25 | 12.48 | 32.87 | 174.04 | 汽车 | ...

Group 1 - The core viewpoint of the article is that Jianfa Zhixin (301584.SZ) has officially listed on the A-share market, experiencing a significant intraday increase of 427.94%, reaching a price of 37.22 yuan [1] - Jianfa Zhixin is a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables to end hospitals [1] - The IPO price was set at 7.05 yuan per share, with a total of 63.1933 million shares issued, raising funds mainly for the upgrade of information systems and centralized operation services for medical consumables [1] Group 2 - The implementation of the projects funded by the IPO is expected to significantly enhance the company's information system support capabilities, improve refined and intelligent operational levels, and provide a solid technical foundation for the continuous expansion of business scale and efficient management [1] - Analysts indicate that by deeply integrating information management with traditional medical device distribution, Jianfa Zhixin has developed into one of the leading companies in the domestic high-value medical device distribution sector [1] - Post-listing, the company is expected to further strengthen its competitive advantage in the industry and consolidate its market position, leveraging the resources of Xiamen Jianfa Group and its state-owned background [1]

Group 1 - The stock of N Jianfa surged over 400% at the beginning of trading [1] - Jianfa Zhi Xin is a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices [1] - The company provides centralized operation services for medical consumables (SPD) to end hospitals [1]

Core Insights - Three companies have recently been listed on different stock exchanges, with their respective issuance prices and price-earnings ratios provided [1][2][3][4]. Group 1: Company Listings - Jianfa Zhixin was listed on the Shenzhen Stock Exchange's ChiNext with a stock code of 301584, an issuance price of 7.05 CNY per share, and a price-earnings ratio of 13.29 [2]. - United Power was listed on the Shenzhen Stock Exchange's ChiNext with a stock code of 301656, an issuance price of 12.48 CNY per share, and a price-earnings ratio of 32.87 [3]. - Jinhua New Materials was listed on the Beijing Stock Exchange with a stock code of 920015, an issuance price of 18.15 CNY per share, and a price-earnings ratio of 11.95 [4]. Group 2: Company Profiles - Jianfa Zhixin specializes in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [2]. - United Power aims to be a global leader in intelligent electric vehicle components and solutions, focusing on core components of power systems such as electric drive systems and power supply systems [3]. - Jinhua New Materials is engaged in the research, production, and sales of ketoxime series fine chemicals [5].